Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of liraglutide on skeletal muscle transcriptome in diet-induced obese C57BL/6 mice

ABSTRACT: Metabolic diseases have become a major global health burden. Insulin resistance plays a critical role in the development and progression of metabolism‑related disorders. Glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs) have emerged as groundbreaking therapeutic agents for the management of a wide spectrum of metabolic diseases. As skeletal muscle is the primary site of insulin‑stimulated glucose disposal, and muscle insulin resistance is a central feature of abnormal glucose metabolism in obesity. To investigate the effects of GLP‑1RAs on the transcriptomic profile of skeletal muscle, we administered liraglutide to diet‑induced obese (DIO) mice and collected skeletal muscle tissues for transcriptome sequencing.

ORGANISM(S): Mus musculus

PROVIDER: GSE324755 | GEO | 2026/03/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-Seq analysis on the liver of mice treated with high-fat diet and liraglutide

Project description:GLP-1 based diabetes drugs are effective to reduce hepatic lipid accumulation beyong glycemic control. As GLP-1 receptor (GLP-1R) is not expressed in hepatocytes, the mechanism behind the beneficial effects of GLP-1 based drugs on the liver remained elusive. Several studies have shown that the expression of hepatic fibroblast growth factor 21 (FGF21) can be stimulated by GLP-1-based drugs. Therefore, the present study aimed to assess such stimulation in mice and in mouse primary hepatocytes, determine whether hepatic FGF21 mediates functions of the GLP-1R agonist liraglutide, and to explore the potential mechanisms of liraglutide regulating the expression of FGF21. In high-fat diet induced obese mice, we observed hepatic and plasma FGF21 elevation, improved glucose disposal, and reduced plasma triglyceride levels by liraglutide treatment. Moreover, RNA-sequencing on the liver suggested that Fgf21 was the most upregulated gene after liraglutide treatment. In liver-specific FGF21 knock-out mice on high-fat and high-fructose diet, the body-weight gain attenuation and lipid homeostatic effects of liraglutide was lost or significantly reduced. These studies implied that hepatic FGF21 was the critical mediator of liraglutide-induced metabolic improvement.

2021-03-16 | GSE168937 | GEO

Pharmacodynamic effects of GLP-1 agonist liraglutide in adolescent, prediabetic pigs

Project description:GLP-1 agonists are potent glucose-lowering agents, however, their effect on adolescent organisms needs to be clarified Transgenic pigs expressing a dominant-negative GLP receptor randomly assigned for a 90 day treatment trial with liraglutide (0.6-1.8 mg per day)/placebo

2015-12-31 | E-GEOD-56427 | biostudies-arrayexpress

Glucose sensing by skeletal myocytes couples nutrient signaling to systemic homeostasis

Project description:Skeletal muscle is a major site of postprandial glucose disposal. Inadequate insulin action in this tissue contributes to hyperglycemia in type 1 and type 2 diabetes. While glucose is known to stimulate insulin secretion by pancreatic b cells, whether it directly engages nutrient-sensing pathways in skeletal muscle to regulate glucose metabolism remains largely unexplored. Here we identified the Baf60c-Deptor-AKT pathway as a target of muscle glucose sensing that augments insulin action in skeletal myocytes. Genetic activation of this pathway improves postprandial glucose disposal in mice, whereas the muscle-specific ablation impaired insulin action and led to glucose intolerance. Mechanistically, glucose triggers a rapid calcium response in myocytes that acts on the class IIa histone deacetylase HDAC5, leading to Baf60c induction and insulin-independent AKT activation. The pathway is engaged by the anti-diabetic drugs sulfonylureas, suggesting that its therapeutic activation may have beneficial effects on glycemic control in diabetes. We used microarrays to elucidate the role of of Baf60c in transcriptional regulation by glucose in skeletal myocytes.

2017-04-20 | GSE79925 | GEO

Molecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety

Project description:Liraglutide and other agonists of the glucagon-like peptide 1 receptor (GLP-1RAs) are effective weight-loss drugs, but how they suppress appetite remains unclear. One potential mechanism is by activating neurons which inhibit hunger-promoting Agouti-related peptide (AgRP) neurons of the arcuate hypothalamus (Arc). To identify these afferents, we developed a method combining rabies-based connectomics with single-nuclei transcriptomics. Applying this method to AgRP neurons predicted at least 21 afferent subtypes in the mouse mediobasal and paraventricular hypothalamus. Among these are Trh+ Arc neurons (TrhArc), inhibitory neurons which express the Glp1r gene and are activated by the GLP-1RA liraglutide. Activating TrhArc neurons inhibits AgRP neurons and feeding, likely in an AgRP neuron-dependent manner. Silencing TrhArc neurons causes over-eating and weight gain and attenuates liraglutide’s effect on body weight. Our results demonstrate a widely applicable method for molecular connectomics, comprehensively identify local inputs to AgRP neurons, and reveal a circuit through which GLP-1RAs suppress appetite.

2024-10-07 | GSE277578 | GEO

GLP-1 receptor signaling increases PCSK1 and beta-cell features in human alpha-cells

Project description:Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose stimulated insulin secretion. GLP-1 is classically produced by gut L cells; however, under certain circumstances alpha-cells can express the prohormone convertase required for proglucagon processing to GLP-1, prohormone convertase 1/3 (PC1/3), and can produce GLP-1. However, the mechanisms through which this occurs are poorly defined. Understanding the mechanisms by which alpha-cell PC1/3 expression can be activated may reveal new targets for diabetes treatment. Here, we demonstrate that the GLP-1 receptor (GLP-1R) agonist, liraglutide, increases alpha-cell GLP-1 expression in a beta cell GLP-1R-dependent manner. We demonstrate that this effect of liraglutide is translationally relevant in human islets through application of a new scRNA-sequencing technology, DART-seq. We find that the effect of liraglutide to increase alpha-cell PC1/3 mRNA expression occurs in a sub-cluster of alpha-cells and is associated with increased expression of other beta-cell-like genes, which we confirm by IHC. Finally, we find that the effect of liraglutide to increase bi-hormonal insulin+ glucagon+ cells is mediated by the beta-cell GLP-1R in mice. Together, our data validate a new high-sensitivity method for scRNA-sequencing in human islets and identify a novel GLP-1 mediated pathway regulating human alpha-cell function.

2020-12-24 | GSE163744 | GEO

Liraglutide inhibits osteoclastogenesis and improves bone loss by down-regulating Trem2 in female type 1 diabetic mice: findings from transcriptomics

Project description:Aims:We aimed to explore possible mechanisms of bone loss in T1D and clarify whether liraglutide have effects on bone quality of T1D mice using transcriptomics, . Methods:Female streptozotocin-induced diabetic C57BL/6J mice were randomly divided into 4 groups and received the following treatments daily for 8 weeks: saline as controls; insulin; liraglutide; liraglutide combined with insulin. These groups were also compared to non-STZ-treated normal glucose tolerance (NGT) group. Trunk blood and bone tissues were collected for analysis. Three tibia from each of the NGT, saline treated and liraglutide treated group were randomly selected for transcriptomics. Results:Compared with NGT mice,saline treated T1D mice manifested markedly hyperglycemia and weight loss, and micro-CT revealed significantly lower bone mineral density(BMD) and deficient microarchitectures in tibias.8 weeks’ treatment with liraglutide alone or combined with insulin rescued the decreased BMD and partly corrected compromised trabecular microarchitectures. Transcriptomics analysis showed there were 789 differentially expressed genes mainly mapped to osteoclastogenesis and inflammation pathways.RT-qPCR verified gene expression of Trem2, Nfatc1, Trap and Ctsk were significantly increased in tibia of T1D compared to that in NGT group. Liraglutide treatment alone or combined with insulin could effectively suppress osteoclastogenesis by down-regulating gene expression of Trem2, Nfatc1, Ctsk and Trap.

2021-11-21 | GSE189112 | GEO

dbdbLiraglutide - Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice

Project description:db/db mouse kidney given liraglutide or insulin compared to db/db vehicle and healthy vehicle, 12 weeks dosing, all included db/db mice over 16 mM blood glucose level.

2017-03-29 | PXD002988 | Pride

Gene expression alternations in liraglutide treated rats cardiac muscle

Project description:Diabetic rats changes gene exprssion in liraglutide treated rats cardiac muscle

2018-03-28 | GSE102194 | GEO

Signatures of Proteomics and Glycoproteomics Reveal Liraglutide Ameliorates NAFLD by Regulating Specific Metabolic Homeostasis in Mice

Project description:Liraglutide, a GLP-1 receptor agonist approved for diabetes and obesity, shows promise in treating NAFLD, the most prevalent chronic liver disease globally. Despite its therapeutic potential, the systematic molecular regulations underlying Liraglutide effects on NAFLD remain underexplored, indicating the crucial need to fully understand its mechanism and facilitate its use in NAFLD treatment.Based on this,we established NAFLD modele by feeding C57/BL6 mice a high-fat diet (HFD). After administration of liraglutide injection to HFD mice, liver biochemical parameters were measured to assess the efficacy of liraglutide. Mouse livers were extracted for label-free quantitative proteomics and glycoproteomics analysis to summarize the mechanism of action of liraglutide in ameliorating NAFLD. Meanwhile, liraglutide hydrogels were prepared and characterized to extend the interval of liraglutide injection administration. Our research showed that liraglutide therapeutic effect on NAFLD was largely driven by significant glycosylation changes, which have a more profound impact than changes in overall protein expression. These insights into Liraglutide regulatory networks and targets offered valuable guidance for optimizing NAFLD treatment and advancing its clinical application.

2025-12-15 | PXD055468 | Pride

Chemical Systems Biology Reveals Mechanisms of Dissociated Glucocorticoid Receptor Signaling

Project description:Glucocorticoids display remarkable anti-inflammatory activity, but their use is limited by undesirable on-target effects including insulin resistance and skeletal muscle atrophy. We used a chemical systems biology approach called Ligand Class Analysis (LCA) to examine ligands designed to alter the receptor through distinct structural mechanisms. These ligands displayed a full range of activity profiles, providing the variance required to identify ligand-specific gene expression and transcriptional coregulator interaction patterns that were highly predictive of their effects on myocyte glucose disposal and protein balance. Anti-inflammatory effects were linked to inhibition of glucose disposal in skeletal muscle but not to muscle atrophy. This approach successfully predicted dissociated activity in vivo, identifying compounds that were muscle sparing or anabolic for protein balance and mitochondrial potential. LCA defines the mechanistic links between the ligand-receptor interface and the physiological outcomes of the ligands, a general approach that can be applied to any ligand-regulated allosteric signaling system.

2020-09-08 | GSE149453 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data